In February, the U.S. Food and Drug Administration issued draft guidance designed to assist researchers in developing treatments for patients in the early stages of AD, before noticeable dementia.
The initiative sidesteps a years-long stalemate in Congress over the Dream Act, draft legislation designed to legalize undocumented young people that has been ensnared in a broader debate about immigration overhaul.
The United Nations Security Council in New York has adjourned its debate on the crisis, saying it needs more time to discuss a draft resolution designed to put pressure on Israel to withdraw.